30694-25-8

Basic information

• Product Name: isopropyl 4-aminophenylcarbamate
• Synonyms: isopropyl 4-aminophenylcarbamate
• CAS NO: 30694-25-8
• Molecular Weight: 0
• Mol File: 30694-25-8.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: isopropyl 4-aminophenylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: isopropyl 4-aminophenylcarbamate(30694-25-8)
• EPA Substance Registry System: isopropyl 4-aminophenylcarbamate(30694-25-8)

Safety Data

• Hazardous Substances Data: 30694-25-8(Hazardous Substances Data)

Upstream product

• 100-28-7 4-Nitrophenyl isocyanate 
• 67-63-0 isopropyl alcohol 
• 530-62-1 1,1'-carbonyldiimidazole 
• 106-50-3 1,4-phenylenediamine 
• 122-42-9 carbamic acid, phenyl-, 1-methylethyl ester 
• 303158-02-3 (4-nitroso-phenyl)-carbamic acid isopropyl ester 
• 108-23-6 isopropyl chloroformate 
• 122-80-5 N-acetyl-p-phenylenediamine 
• 14357-51-8 isopropyl N-(4-nitrophenyl)carbamate 

Downstream Products

• 35198-91-5 2-acetamido-5-isopropoxycarbonylamino-1-nitrobenzene 
• 629648-18-6 (4-acetylamino-phenyl)-carbamic acid isopropyl ester 

Relevant articles and documents

Synthesis and structure-activity relationships of (aryloxy)quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors

In our continuing search for medicinal agents to treat proliferative diseases, quinazoline derivatives were synthesized and evaluated pharmacologically as epithelial growth factor receptor and vascular endothelial growth factor receptor 2 (VEGFR-2) tyrosine kinase inhibitors. A quantitative structure-activity relationship analysis was conducted to rationalize the structure-activity relationship and to predict how similar the inhibitor-binding profiles of two protein kinases are likely to be on the basis of the docking of lead coumpounds into the ATP-binding site. This model was used to direct the synthesis of new compounds. A series of N-(aromatic)-N′-{4-[(6,7- dimethoxyquinazolin-4-yl)oxy]phenyl}urea were identified as potent and selective inhibitors of the tyrosine kinase activity of VEGFR-2 (fetal liver kinase 1, kinase insert domain-containing receptor). An efficient route was developed that enabled the synthesis of a wide variety of analogues with substitution on several positions of the template. Substitution of diarylurea, competitive with ATP, afforded several analogues with low nanomolar inhibition of enzymatic activity of VEGFR-2. In this paper, we describe the synthesis, structure-activity relationships, and pharmacological characterization of the series.

Identification of compounds for the treatment or prevention of proliferative diseases

The invention features compounds for the treatment of cancer and other proliferative diseases. These compounds were identified in screening assays that contact candidate compounds with a cell containing a nucleic acid that includes a HER2 regulatory element and a reporter sequence. The invention further features compounds structurally related to those identified by the screening assays. Finally, the invention features methods of treating or preventing a proliferative disease using the compounds of the invention.

Synthesis of alkyl N-(C-nitrosoaryl)carbamates and some reactions thereof

Reactions of alkyl N-phenylcarbamates, m-di(methoxycarboxyamido)benzene, and methyl N-(o-tolyl)carbamate with nitrosylsulfuric acid in glacial acetic acid afford N-(C-nitrosoaryl)carbamates; under these conditions tert-bulyl N-phenylcarbamate suffers decarboxylation, methyl N-(p-tolyl)-, methyl N-(p-methoxyphenyl)carbamates, o-and p-di(methoxycarboxyamido)benzenes are nitrated, and isomeric methyl N-nitrophenylcarbamates and methyl N-(p-bromophenyl)carbamate do not react. The reduction of N-(C-nitrosoaryl)carbamates with dithionite afforded the corresponding aminocarbamates; the oxidation with nitric acid yielded carbamate nitro derivatives; the condensation with aniline and benzylpyridinium chloride resulted in carbamate derivatives of azobenzene and phenylnitron.